The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...